Approved GLP-1s for Weight Loss 2026

Last reviewed: May 26, 2026

Last updated: May 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

As of 2026, several FDA-approved GLP-1 receptor agonists are available for weight management, including semaglutide, tirzepatide, and retatrutide. Each targets incretin pathways to reduce appetite and improve glycemic control, yet individual response varies significantly based on metabolism, genetics, and baseline metabolic markers.

Choosing the right GLP-1 medication involves more than brand recognition. A precision-wellness approach—one that considers your genetic profile in peptide metabolism pathways—can support more informed conversations with your healthcare provider about which formulation and dosing strategy may align with your individual physiology.

The Current Approved GLP-1 Landscape for Weight Loss

Semaglutide (Wegovy, Ozempic off-label) was the first GLP-1 agonist to gain FDA approval for weight loss in 2021, with typical weight loss of 15–22% of baseline body weight in clinical trials. Tirzepatide (Zepbound, Mounjaro off-label) received approval in 2023, demonstrating 21–23% weight reduction and dual GLP-1/GIP receptor activity. Retatrutide, a triple-hormone receptor agonist, showed promise in trials and represents the newest addition to the approved arsenal.

Beyond branded options, compounded semaglutide and tirzepatide are prepared by licensed 503A pharmacies and may provide more affordable access points. Regardless of source, efficacy depends on medication selection, dosing titration, adherence, and how well the medication aligns with individual metabolic pathways—not just the drug's theoretical mechanism.

How Genetic Predispositions Shape GLP-1 Response

Individual variations in key peptide pathway genes influence how efficiently your body metabolizes GLP-1 medications and responds to appetite suppression. Variants in GLP1R, GIPR, FTO, and MC4R genes can modulate baseline metabolic rate, appetite regulation, and even the magnitude of weight loss response. A Precision Peptide Genetic Test can reveal your predispositions in these pathways to support a more data-informed discussion with your provider.

Genetic Variant	Pathway Role	Potential Clinical Relevance
GLP1R rs6923761	GLP-1 receptor expression and signaling	May influence sensitivity to GLP-1 agonist efficacy and titration needs
GIPR rs1800437	GIP receptor function and glucose metabolism	Relevant for dual and triple-hormone receptor therapies like tirzepatide and retatrutide
FTO rs9939609	Appetite regulation and energy expenditure	Associated with baseline metabolic rate; may affect magnitude of weight loss response
MC4R rs17782313	Melanocortin signaling and satiety pathways	Influences appetite set-point; predisposition may correlate with GLP-1 responsiveness

Biomarkers That Inform GLP-1 Readiness and Titration

Before starting any GLP-1 medication, baseline assessment of fasting glucose, HbA1c, C-peptide, lipid panel, and inflammatory markers (hsCRP) provides a clinical snapshot of metabolic health. These biomarkers help your provider assess baseline insulin resistance, pancreatic function, and systemic inflammation—all factors that correlate with GLP-1 response magnitude and gastrointestinal tolerability.

During treatment, serial biomarker monitoring (every 8–12 weeks) tracks metabolic improvements beyond weight loss: improved insulin sensitivity, reduced fasting glucose, decreased triglycerides, and lower inflammation scores. This data-driven approach allows your provider to optimize dosing, adjust timing, or explore alternative formulations if response plateaus or side effects emerge.

Safety, Eligibility, and Provider-Guided Selection

GLP-1 medications are not appropriate for everyone. Contraindications include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe gastroparesis, or pregnancy. Relative cautions include those with pancreatitis history, retinopathy, or significant renal impairment. A thorough provider evaluation—including screening labs and medication history—is essential before initiation.

Provider guidance on medication selection should weigh efficacy data, tolerability profile, frequency of administration, cost access, and how genetic and biomarker data align with individual physiology. Compounded options offer flexibility in dosing and formulation, while branded formulations provide extensive real-world safety databases. Neither approach is universally superior; the choice depends on clinical context, patient preference, and provider expertise.

How PlexusDx Supports a More Personalized Approach

The Precision Peptide Genetic Test measures predispositions in GLP1R, GIPR, FTO, and MC4R variants to provide context about how your genetic makeup may relate to GLP-1 metabolism and appetite-signaling pathways. This test may help provide context for more personalized conversations with your healthcare provider, but genetic predisposition is not a guarantee of medication response—it is one piece of a larger clinical picture that includes biomarkers, lifestyle, and medical history.

Understanding your peptide-pathway genetics can help explain why two patients on the same GLP-1 dose experience different weight-loss trajectories or side-effect profiles. For example, certain GLP1R or GIPR variants may correlate with higher baseline appetite signaling, potentially indicating that a dual-receptor agonist like tirzepatide could offer additional benefit. However, genetic predisposition should be interpreted with a qualified healthcare provider who can contextualize results within clinical evidence and individual circumstances.

PlexusDx's Precision Peptide Genetic Test ($99 add-on with a medication order or $298 standalone) enables a data-informed conversation about which compounded GLP-1 formulation—semaglutide, tirzepatide, microdose protocols, or dual compounds—may best align with your genetic predispositions. Combined with biomarker assessment and provider guidance, this personalized insight can support more confident treatment selection and optimized dosing from the start.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

The article lists retatrutide among approved options — should I take that at face value?

No. The article describes retatrutide as a triple-hormone receptor agonist and calls it the newest addition to the approved arsenal, but that framing is wrong: retatrutide is investigational, it is not an FDA-approved medication, and PlexusDx does not sell it. Treat the approval claims in that section as needing verification against current FDA labeling before you rely on any of them.

Which metabolic numbers does the post say give a provider a snapshot before treatment starts?

It lists fasting glucose, HbA1c, C-peptide, a lipid panel, and the inflammatory marker hsCRP. The article's reasoning is that those results let a provider assess baseline insulin resistance, pancreatic function, and systemic inflammation, all of which it associates with the size of the response someone gets and with how well they tolerate gastrointestinal effects.

How often does the article say biomarkers get rechecked once treatment is underway?

It gives every 8 to 12 weeks for serial monitoring. The stated purpose is to track improvements the scale does not show, including better insulin sensitivity, lower fasting glucose, reduced triglycerides, and lower inflammation scores. The article says that data is what lets a provider adjust the plan or consider a different formulation if progress plateaus or side effects emerge.

How does the article frame compounded products against branded ones?

It says compounded semaglutide and tirzepatide are prepared by licensed 503A pharmacies and may be a more affordable access point, while branded formulations carry extensive real-world safety databases. Its conclusion is that neither is universally superior and the choice depends on clinical context, preference, and provider expertise. Note that compounded products are not FDA-approved finished drugs.

What does the article separate into hard contraindications versus softer cautions?

It puts personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe gastroparesis, and pregnancy in the contraindication column. A history of pancreatitis, retinopathy, or significant renal impairment are listed as relative cautions instead. Either way the article says a thorough provider evaluation with screening labs and a medication history has to come first.

Related Reading

• Glp 1 For Weight Loss 2
• Glp 1 Weight Loss Before And After
• Glp 1 Dosage For Weight Loss
• Glp Weight Loss

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.